We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. (PRO-LAPS I)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2012 by Cecilia Becattini, University Of Perugia.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01589146
First Posted: May 1, 2012
Last Update Posted: May 1, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Cecilia Becattini, University Of Perugia
  Purpose

Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE.

The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.


Condition Intervention Phase
The Primary Study Objective is to Assess the Efficacy and Safety of Extended 4-week Heparin Prophylaxis Compared to Prophylaxis Given for 8±2 Days After Planned Laparoscopic Surgery for Colorectal Cancer. The Clinical Benefit Will be Evaluated as the Difference in the Incidence of VTE or VTE-related Death Occurring Within 30 Days From Surgery in the Two Study Groups. Drug: Heparin, Low-Molecular-Weight Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.

Resource links provided by NLM:


Further study details as provided by Cecilia Becattini, University Of Perugia:

Primary Outcome Measures:
  • symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death [ Time Frame: 30 days ]

Estimated Enrollment: 400
Study Start Date: September 2010
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: short heparin
Experimental: extended heparin Drug: Heparin, Low-Molecular-Weight
4 weeks heparin prophylaxis

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consecutive patients who had
  • planned laparoscopic surgery for
  • colorectal cancer will be included in the study provided no exclusion criteria will be found

Exclusion Criteria:

  • age < 18 years
  • surgery for non-cancer disease
  • duration of surgery < 45 min
  • other indication for anticoagulant therapy
  • known cerebral metastases
  • kidney or liver failure
  • known hemorrhagic diathesis or high risk for bleeding
  • history of intracerebral bleeding or neurosurgery within 6 months, history of heparin induced thrombocytopenia
  • pregnancy or lactation
  • refusal of informed consent.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01589146


Contacts
Contact: Cecilia Becattini +39 075 5786424 cecilia.becattini@unipg.it

Locations
Italy
Internal and Cardiovascular Medicine - University of Perugia Recruiting
Perugia, Italy
Sponsors and Collaborators
University Of Perugia
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Cecilia Becattini, MD, University Of Perugia
ClinicalTrials.gov Identifier: NCT01589146     History of Changes
Other Study ID Numbers: Unipg-CRU-01-2012
First Submitted: April 28, 2012
First Posted: May 1, 2012
Last Update Posted: May 1, 2012
Last Verified: April 2012

Keywords provided by Cecilia Becattini, University Of Perugia:
colon-rectal cancer
heparin
prophylaxis
laparoscopy

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Calcium heparin
Heparin
Heparin, Low-Molecular-Weight
Dalteparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action